'Cons of 'Brexit' for pharma would far outweigh pros'
This article was originally published in SRA
Executive Summary
Any benefits of the UK leaving the EU would be far outweighed by the disadvantages in the pharmaceutical and healthcare sector – not least the loss of participation in EU research projects and clinical trials – and could lead to a loss of jobs and a downturn in inward investment in the UK.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.